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A proposal is made for the chemical, physical and clinical definitions of human bilirubin and bilirubin compounds. The necessity for
new definitions has been stressed in the discussions at international bilirubin meetings. This was followed up by IFCC (International
Federation of Clinical Chemistry) when, in 1970, it elected an expert panel on bilirubin. No proposals have so far been made by this
New findings published and presented during the last few years make it still more needful to give a general review of the problems
connected to bilirubin nomenclature.
Es wird ein Vorschlag für die chemische, physikalische und klinische Definition von menschlichem Bilirubin und Bilirubin-Verbindungen
gemacht. Die Notwendigkeit neuer Definitionen wurde in den Diskussionen auf internationalen Bilirubin-Tagungen betont, Dies wurde
auch von der IFCC (International Federation of Clinical Chemistry) verfolgt, als sie 1970 eine Experten-Kommission für Bilirubin wählte.
Bisher hat diese Kommission keine Vorschläge gemacht. Die in den letzten Jahren veröffentlichten und vorgetragenen neuen Ergebnisse
machen es noch erforderlicher, eine generelle Übersicht über die Probleme, die mit der Bilirubin-Nomenklatur verbunden sind, zu geben.
Bilirubin is formed in humans, as far as it is known,
today, as a degradation product of protoporphyrin.
Hemoglobin, which is the most abundant source for
bilirubin production, contains ferroprotoporphyrin IX
(one of the 15 possible isomers of protoporphyrin). It
has been proved that, in vivo, this porphyrin is cleaved
at the oc-bridge only, resulting in a bilirubin IX (1).
It is doubtful that this is the only isomer of bilirubin
formed in vivo, because the III& and XIII# isomers
have been isolated from commercial bilirubin prepared
from natural sources. Bilirubins from other porphyrins
have, so far, not been identified.
It must be emphasi2ed that chemically pure bilirubin in
the crystalline state and bilirubin bonded to proteins,
Hpids and membrane structures in the dynamic state of
the living cell may behave quite differentely, and that
tautomeric forms and steric structures of bilirubin
which are present even in trace amounts only, in pure
preparations, may be the dominating structures in vivo.
This could explain the many difficulties in handling bili-
rubin and bilirubin compounds when they are present
in biological materials.
Chemically "pure" Bilirubins
McDoNAGH and Assis (2) discovered that three bilirubin
isomers were present in some commercial preparations
of bilirubin. One of the commercial preparations
supposed to be especially pure (3) contained 16% Ilia,
22% XIIIoc and only 62% of bilirubin IXa. Isomers were
not found if bilirubin IX# was treated with alkaline
solution, while acid treatment immediately gave the
theoretical yield of 25% Ilia, 50% IX* and 25% XIII*
isomers with a transitory cleavage of the central methyl-
ene bridge and a random reunion of the dipyrrols (4).
After an hour the isomer dominated. Isomeriza-
tion of porphyrinogens in hot acid is also well known (5).
Whether the bilirubin IX# is the only bilirubin in vivo
and the other isomers are products of purification only,
is not yet clear.
It is surely the multiplicity of degrading pathways which
decide the fate of different porphyrins. The end product
can be bilirubin IXoc as from protoporphyrin IX, di-
pyrrols, or probably even still simpler compounds.
Tab. 1
Bilirubin (in lactam from) and its isomers
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Bilirubin may exist in several tautomeric forms: 1. Elec-
trons ( ) can move intramolecularly within the two
halves of the molecule because of the unbroken row of
conjugated double bonds. Electrons can thereby be
dislocated from a vinyl (on ring A or D) to the middle
bridge (b) resulting in a dihydrobiliverdin (6).
2. The pyrrol-rings A and D can exist either in lactam or
in lactim forms (7).
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3. Intramolecular hydrogen bonds can exist between one
or both of the two carboxyl groups and pyrrol-N (8, 9,
10) or between the two carboxyl groups.
4. It was proposed (11) that the vinyl on ring D forms
a furan ring with a lactim hydroxyl on ring D, and
although this has been disproved in vitro (12), it may
still occur in vivo.
5. With the pyrrol rings A and D or D and A, respective-
ly, in lactam and lactim form, the whole molecule may
condense into a ring-structure kept together by hydrogen
bindings (ring A-O-H-O-ring D) (13, 14, 15, 16).
6. Numerous steric structures are possible, and the
structure present in a certain situation depends on the
neighbouring molecules.
Bilirubin in Biology
We know nothing about the tautomeric form or forms
of bilirubin present in biological fluids. In particular, we
know nothing about the bilirubin molecule when it is
linked to the specific site on the microsomal enzyme.
Physical and chemical conditions affecting esterification
of bilirubin may just as well influence the equilibrium
between different forms of bilirubin as the enzyme it-
self.
Bilirubin and bilirubin-compounds as they are found in
man can be classified either according to their peculiar
qualities or to their localisation. A chemical, a physical
and a clinical classification are necessary to cover the
whole biological field of bilirubin in humans. It is still
too early to classify bilirubins as to their origin corre-
sponding to pathohem, heme, heme a and heme a2
A chemical classification is necessary to give exact names
to properly identified compounds. A physical classifi-
cation is important because the different compounds
have to be fractioned and purified by physical methods.
Clinically, the important points are the synthesis, trans-
portation, accumulation, toxicity, and excretion of the
different compounds.
Chemical classifications
Bilirubin (earlier called unconjugated bilirubin)
1. Bilirubin-proteins
a) bilirubin-albumin
b) bilirubin-specific liver proteins (Y & Z). (18)
c) bilirubin^other proteins including enzyme^bonded
bilirubin
2. Bilirubin-phospholipid-albumin (12,' 19, 21, 22).
3. "Free" bilirubin (not protein-bonded) (22).
4. Bilirubin-metal-complexes (24, 25).
Bilirubin-esters (earlier called conjugated bilirubin)
1. Bilirubin mono- or digesters
a) with glucose (/S-glucoside) (26, 27)
b) with glucuronic acid (0-glucuronide) (28, 29, 30, 31)
c) with xylose (/?-xyloside) (26)
d) with disaccharides (ß-disaccharide) (32)
2. Bilirubinesters-phospholipid-albumin (32).
The terms conjugated and unconjugated bilirubin
should be avoided, both because these words are used
for so many different compounds (ethers, glucuronic
acid linked to nitrogen in aromatic compounds), and
because the word conjugated is used for other purposes
in organic chemistry. With bilirubin, only esters have
been identified to date. Seen from the bilirubin molecule
the link is an ester, therefore, bilirubin ester, while the
compound seen from the sugar side is a "glucoside".
The esters.with glucuronic acid and xylose, for instance,
are therefore called bilirubin glucuronide and bilirubin
xyloside.
Bilirubin seems to be bonded to a specific site on the
albumin molecule. One molecule of albumin binds one
molecule of bilirubin very tightly and a second molecule
more loosely (34). The specific liver cell proteins (Y & Z)
are supposed to represent intracellular transport proteins
for bilirubin (18). This is still disputed because of
unfavorable equilibrium constants for the bilirubin-
albumin bond. However, experiments done in vitro tell
very little about how the bilirubin-protein bonds behave
within the living liver cell.
Both bilirubin and bilirubin esters form complexes with
phospholipids. They are extractable from serum with
diethylether and are usually called ether-soluble bili-
rubin (35). The link between bilirubin and the phospho-
lipid is usually broken by ethanol (20).
"Free" bilirubin is a fraction of serum bilirubin which
under certain circumstances is oxidized to biliverdin by
peroxidase, while bilirubin bonded to albumin is
resistant to this treatment (23). However, this "free"
bilirubin may be bonded to peptides, amino acids or
other small molecules present in serum and, therefore,
it is for the moment reasonable to call this fraction: non-
protein-bonded bilirubin. Bilirubin-aminoacid com-
plexes, for instance, can be formed in vitro (36).
Bilirubin-metal complexes have been made in vitro (24,
25) and there are no reasons not to believe that such
complexes can. also exist in vivo, especially since bili-
rubin can take on a ring-like configuration with one of
the end pyrrol-rings in a lactim form and the other in
a lactam form (see above).
The question of the existence of monoesters of bilirubin
(37) has been under discussion for a long time. Their
probable existence has now been settled by Chromato-
graphie studies of amides formed from bilirubin esters
(38). It is assumed on the basis of considerable evidence
that two forms of "monoesters" can be present, one a
complex of bilirubin and bilirubindiester, and the other
a true monoester (39).
Bilirubin esters with glucose and xylose have been
identified in dog bile (40, 41) and also in human bile (42).
These esters are formed by liver homogenates in the
presence of UDP-glucose or UDP-xylose (27, 42). That
Z. Klin. Chem. Klin. Biochem./ 10. Jahrg. 1972 / Heft 12
564 Fog and Bakken: Definitions of human bilirubin and bilirubin compounds
glucosides and xylosides are formed together with the







It is important for bilirubin esterification that UDP-
glucuronic acid is a relatively weak competitor of UDP-
glucose while the inhibition by UDP-xylose is much
more pronounced (42).
However, it is astonishing that, up to date, esters with
galactose have not been found in spite of the close
relation of \ UDP-galactose to UDP-glucose. Trace







The esters with disaccharides isolated and described by
KÜNZLE (32) are probably products formed by the
numerous glucosidases and glucosidetransferases present
in the liver cell which can add another monosaccharide
to the glucuronic acid on bilirubin glucuronide or to
glucose on the glucoside.
Nothing is known of the significance of these different
esters, all identified by different azo-pigment-techniques.
Esters with the monosugars have also been found in the
bile from rats and a number of other animals (42). Even
when the bile ducts in rats are occluded for a short time
there is a shift in the relative amounts of the various






4. bilirubin ionized or dissolved with either complexing
agents or substances opening hydrogen bondings.
Hydrophobe bilirubms
1. bilirubin
a) with intramolecular hydrogen bonds (intramolecular
complexes).




b) with bilirubin esters
It is of utmost importance to have bilirubins classified
according to their hydrophile or hydrophobe nature,
and in the future it will be desirable to have still more
exact values for thes^ qualities than the chromato-
graphical behaviour and Ap-values of their azo-pig-
ments.
The distribution of bilirubin between water and chloro-
form depends, for instance, on the carboxyl on the
propionyl groups. If the are ionized, bilirubin is almost
totally transferred into the water phase, while non-
ionized bilirubin-carboxyl groups are "hidden" by
intramolecular hydrogen bonds, as described above, so
non-ionized bilirubin is almost completely extracted
into the chloroform.
With increasing concentration, bilirubin has a tendency
to polymerize, both in hydrophilic and hydrophobic
solutions (14, 46).
Clinical classification
Icterus due to bilirubin^ only
1. Premicrosomal
a) prehepatic as with hemolytic icterus
b) intrahepatic due to transport inhibition or defect
as with flavispidic acid (17)
2. Microsomal
a) intrahepatic as with enzyme inhibition or defect 2.5 in
GILBERT'S disease.
Icterus due to bilirubin esters and bilirubin
3. Postmicrosomal
a) intrahepatic
<x) excretory inhibition or defect as in DUBIN-JOHNSON
disease.
) intrahepatic cholestasis as with chlorpromazin
b) posthepatic
(x) extrahepatic cholestasis
It is reasonable to link a clinical classification to the
microsomes (47) instead of the liver cell, because esteri-
fication takes place in the microsomes, and because
defects have been detected both in the intracellular
transport and excretion of bilirubin from the liver.
Clinically, it is possible to determine whether bilirubin
only, or bilirubin esters (postmicrosomal) and .tfilirubin
are present in serum. Traditionally, it is assumed that
the urine contains only bilirubin esters.
Reasonably reliable methods for the quantitative frac-
tionation of serum bilirubin esters and bilirubin have
yet to be published. The difficulties are that the high
protein content in serum makes extraction procedures
difficult without ruining the ester bond, that bilirubin
and especially bilirubin esters are easily oxidized to
biliverdins, that bilirubin and bilirubin esters behave in
the same way when they are linked to phospholipids,
and that isomerization around the middle bridge (b) in
the bilirubin molecule must be avoided.
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In the future it is reasonable to anticipate that bilirubin
and bilirubin esters can be fractionated also from the
serum and urine. Then, it may be possible to show, as it
is anticipated, that the occlusive sequence of bilirubin
and bilirubin esters in serum is: bilirubin, bilirubin
mono-esters, bilirubin diesters, bilirubin esterified by
disaccharides, and then at last a cleavage (39) of the ester
bond with another increase in bilirubin.
It seems today difficult to have any idea about the normal
or pathological proportions of different bilirubins in
human bile, serum or urine and the significance of
quantitative fractionations.
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